QQQ   389.91 (+0.72%)
AAPL   163.76 (-0.61%)
MSFT   329.49 (-0.18%)
FB   310.39 (-0.07%)
GOOGL   2,859.32 (+1.36%)
AMZN   3,437.36 (-0.18%)
TSLA   1,084.60 (-0.95%)
NVDA   321.26 (+2.20%)
BABA   122.00 (-0.40%)
NIO   36.20 (-5.51%)
CGC   10.36 (+4.23%)
AMD   150.68 (+1.05%)
GE   95.23 (+2.40%)
MU   82.88 (-2.67%)
T   23.05 (+3.69%)
F   19.87 (+1.48%)
DIS   147.20 (+3.55%)
PFE   53.04 (-3.00%)
AMC   30.28 (+5.99%)
ACB   6.14 (+2.16%)
BA   202.38 (+7.54%)
QQQ   389.91 (+0.72%)
AAPL   163.76 (-0.61%)
MSFT   329.49 (-0.18%)
FB   310.39 (-0.07%)
GOOGL   2,859.32 (+1.36%)
AMZN   3,437.36 (-0.18%)
TSLA   1,084.60 (-0.95%)
NVDA   321.26 (+2.20%)
BABA   122.00 (-0.40%)
NIO   36.20 (-5.51%)
CGC   10.36 (+4.23%)
AMD   150.68 (+1.05%)
GE   95.23 (+2.40%)
MU   82.88 (-2.67%)
T   23.05 (+3.69%)
F   19.87 (+1.48%)
DIS   147.20 (+3.55%)
PFE   53.04 (-3.00%)
AMC   30.28 (+5.99%)
ACB   6.14 (+2.16%)
BA   202.38 (+7.54%)
QQQ   389.91 (+0.72%)
AAPL   163.76 (-0.61%)
MSFT   329.49 (-0.18%)
FB   310.39 (-0.07%)
GOOGL   2,859.32 (+1.36%)
AMZN   3,437.36 (-0.18%)
TSLA   1,084.60 (-0.95%)
NVDA   321.26 (+2.20%)
BABA   122.00 (-0.40%)
NIO   36.20 (-5.51%)
CGC   10.36 (+4.23%)
AMD   150.68 (+1.05%)
GE   95.23 (+2.40%)
MU   82.88 (-2.67%)
T   23.05 (+3.69%)
F   19.87 (+1.48%)
DIS   147.20 (+3.55%)
PFE   53.04 (-3.00%)
AMC   30.28 (+5.99%)
ACB   6.14 (+2.16%)
BA   202.38 (+7.54%)
QQQ   389.91 (+0.72%)
AAPL   163.76 (-0.61%)
MSFT   329.49 (-0.18%)
FB   310.39 (-0.07%)
GOOGL   2,859.32 (+1.36%)
AMZN   3,437.36 (-0.18%)
TSLA   1,084.60 (-0.95%)
NVDA   321.26 (+2.20%)
BABA   122.00 (-0.40%)
NIO   36.20 (-5.51%)
CGC   10.36 (+4.23%)
AMD   150.68 (+1.05%)
GE   95.23 (+2.40%)
MU   82.88 (-2.67%)
T   23.05 (+3.69%)
F   19.87 (+1.48%)
DIS   147.20 (+3.55%)
PFE   53.04 (-3.00%)
AMC   30.28 (+5.99%)
ACB   6.14 (+2.16%)
BA   202.38 (+7.54%)
NASDAQ:ARNA

Arena Pharmaceuticals Stock Forecast, Price & News

$53.17
+1.25 (+2.41%)
(As of 12/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$50.95
$53.22
50-Day Range
$51.92
$63.74
52-Week Range
$45.50
$85.00
Volume
489,310 shs
Average Volume
486,449 shs
Market Capitalization
$3.25 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.35
30 days | 90 days | 365 days | Advanced Chart
Receive ARNA News and Ratings via Email

Sign-up to receive the latest news and ratings for Arena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Arena Pharmaceuticals logo

About Arena Pharmaceuticals

Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in San Diego, CA.

Headlines

Arena Pharmaceuticals (NASDAQ:ARNA) Shares Gap Down to $59.94
November 18, 2021 |  americanbankingnews.com
Here's what Wall Street expects from Arena Pharmaceuticals's earnings
November 5, 2021 |  markets.businessinsider.com
Arena (ARNA) Q3 Loss Wider Than Anticipated, Revenues Nil
November 5, 2021 |  finance.yahoo.com
11 Best Hemp Stocks To Buy Now
October 29, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ARNA
CUSIP
04004710
Employees
363
Year Founded
1977

Sales & Book Value

Annual Sales
$320 thousand
Price / Sales
10,147.83
Book Value
$18.58 per share

Profitability

Net Income
$-404.73 million
Pretax Margin
-1,575,635.00%

Debt

Price-To-Earnings

Miscellaneous

Free Float
59,602,000
Market Cap
$3.25 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
12/02/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/22/2022

Social Links


MarketRank

Overall MarketRank

2.24 out of 5 stars

Medical Sector

346th out of 1,391 stocks

Pharmaceutical Preparations Industry

150th out of 669 stocks

Analyst Opinion: 4.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions

Is Arena Pharmaceuticals a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Arena Pharmaceuticals stock.
View analyst ratings for Arena Pharmaceuticals
or view top-rated stocks.

How has Arena Pharmaceuticals' stock price been impacted by COVID-19?

Arena Pharmaceuticals' stock was trading at $40.42 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ARNA shares have increased by 31.5% and is now trading at $53.17.
View which stocks have been most impacted by COVID-19
.

When is Arena Pharmaceuticals' next earnings date?

Arena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Arena Pharmaceuticals
.

How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) released its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($3.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($2.53) by $0.68. During the same period last year, the company posted ($1.69) EPS.
View Arena Pharmaceuticals' earnings history
.

When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?

Shares of Arena Pharmaceuticals reverse split on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for ARNA?

9 brokerages have issued 1-year price targets for Arena Pharmaceuticals' stock. Their forecasts range from $80.00 to $120.00. On average, they anticipate Arena Pharmaceuticals' share price to reach $99.56 in the next twelve months. This suggests a possible upside of 87.2% from the stock's current price.
View analysts' price targets for Arena Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Arena Pharmaceuticals' key executives?

Arena Pharmaceuticals' management team includes the following people:
  • Amit Dilip Munshi, President, Chief Executive Officer & Director
  • Laurie D. Stelzer, Chief Financial Officer & Executive Vice President
  • Paul D. Streck, Chief Medical Officer & SVP-Clinical Development
  • Douglas J. Manion, Executive Vice President-Research & Development
  • Douglas A. Bakan, Vice President-Technical Operations

What is Amit Munshi's approval rating as Arena Pharmaceuticals' CEO?

16 employees have rated Arena Pharmaceuticals CEO Amit Munshi on Glassdoor.com. Amit Munshi has an approval rating of 66% among Arena Pharmaceuticals' employees.

What other stocks do shareholders of Arena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Advanced Micro Devices (AMD), (CGC), Inovio Pharmaceuticals (INO), Cytokinetics (CYTK), Micron Technology (MU), NVIDIA (NVDA), Novavax (NVAX), Alibaba Group (BABA), GW Pharmaceuticals (GWPH) and AT&T (T).

What is Arena Pharmaceuticals' stock symbol?

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

Who are Arena Pharmaceuticals' major shareholders?

Arena Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (13.68%), BlackRock Inc. (8.68%), Goldman Sachs Group Inc. (2.33%), Janus Henderson Group PLC (2.03%), Geode Capital Management LLC (1.74%) and Bank of New York Mellon Corp (1.57%). Company insiders that own Arena Pharmaceuticals stock include Amit Munshi, Christopher Cabell, Jayson Donald Alexander Dallas, Kevin Robert Lind, Manmeet Singh Soni, Robert Lisicki, Robert Lisicki, Steven W Spector, Tina Susan Nova and Vincent Aurentz.
View institutional ownership trends for Arena Pharmaceuticals
.

Which major investors are selling Arena Pharmaceuticals stock?

ARNA stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Assenagon Asset Management S.A., BlackRock Inc., Farallon Capital Management LLC, Wellington Management Group LLP, Dimensional Fund Advisors LP, Emerald Mutual Fund Advisers Trust, and Penserra Capital Management LLC. Company insiders that have sold Arena Pharmaceuticals company stock in the last year include Amit Munshi, Jayson Donald Alexander Dallas, Robert Lisicki, and Vincent Aurentz.
View insider buying and selling activity for Arena Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Arena Pharmaceuticals stock?

ARNA stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Suvretta Capital Management LLC, Goldman Sachs Group Inc., Segall Bryant & Hamill LLC, Moore Capital Management LP, Millennium Management LLC, Laurion Capital Management LP, and Pura Vida Investments LLC. Company insiders that have bought Arena Pharmaceuticals stock in the last two years include Amit Munshi, and Jayson Donald Alexander Dallas.
View insider buying and selling activity for Arena Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Arena Pharmaceuticals?

Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arena Pharmaceuticals' stock price today?

One share of ARNA stock can currently be purchased for approximately $53.17.

How much money does Arena Pharmaceuticals make?

Arena Pharmaceuticals has a market capitalization of $3.25 billion and generates $320 thousand in revenue each year. The biopharmaceutical company earns $-404.73 million in net income (profit) each year or ($9.69) on an earnings per share basis.

How many employees does Arena Pharmaceuticals have?

Arena Pharmaceuticals employs 363 workers across the globe.

When was Arena Pharmaceuticals founded?

Arena Pharmaceuticals was founded in 1977.

What is Arena Pharmaceuticals' official website?

The official website for Arena Pharmaceuticals is www.arenapharm.com.

Where are Arena Pharmaceuticals' headquarters?

Arena Pharmaceuticals is headquartered at 6154 Nancy Ridge Drive, San Diego CA, 92121.

How can I contact Arena Pharmaceuticals?

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at (858) 453-7200, via email at [email protected], or via fax at 858-453-7210.


This page was last updated on 12/2/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.